CA1216232A - Composition and process for overcoming snoring - Google Patents
Composition and process for overcoming snoringInfo
- Publication number
- CA1216232A CA1216232A CA000429349A CA429349A CA1216232A CA 1216232 A CA1216232 A CA 1216232A CA 000429349 A CA000429349 A CA 000429349A CA 429349 A CA429349 A CA 429349A CA 1216232 A CA1216232 A CA 1216232A
- Authority
- CA
- Canada
- Prior art keywords
- composition
- composition according
- group
- surface active
- active substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
ABSTRACT
Composition and process for overcoming snoring A composition for overcoming snoring as well as a process for its use is disclosed. The composition according to the invention contains a surface active substance, a pre-serving agent and/or a substance acting bactericidally or fungicidally on the mucous membranes and optionally a substance for softening the mucous membranes in physiological common salt solution as well as optionally further addit-ives which are compatible with the mucous membranes.
Composition and process for overcoming snoring A composition for overcoming snoring as well as a process for its use is disclosed. The composition according to the invention contains a surface active substance, a pre-serving agent and/or a substance acting bactericidally or fungicidally on the mucous membranes and optionally a substance for softening the mucous membranes in physiological common salt solution as well as optionally further addit-ives which are compatible with the mucous membranes.
Description
Composition and process for overcoming snoring The invention concerns a compo~ition for overcoming snoring and a process for its use.
Snoring is a phenomenon which is based on rhoncus S breathing, which may occur among hum~n beings during sleep. Du~ ';o the strain which snoring may place upon other human beings, many attempts have been made to provide a remedy for this phenomenon.
.,~
The cause of snoring are obstructions (unevenness) in the area of the upper respi~atory tracts. During in-halation and exhalation, the air is led via complex flow channels. Unevennesses in these areas lead neces-sarily to turbulences in the air flow. These cause ~5 impediments ~o breathing, which are below the conscious-nçss threshold. The impediments in the flow channels and the turbulences caused thereby have the consequence that locally a low pressure area(suction) is formed.
This leads to fluttering motions of soft,relaxed struct-ures in the area of the air flow channels. In particul--. ar the soft gums are moved backward and forward by tlle above-mentioned turbulences. Although numerous investig-ations have been carried out to preven' snoring, as yet - they have not led to the desired success. These efforts have been based on compositionswhich were built u~ on chel~lo-therapeutics or antibiotics, vasoactive substances, cor-ticoids or on antihistaminics. ~hese ccmpositions, ~.owever, have either proved to be not effective enough to pre-vent snoring over long periods, or when taken over leng-thy periods they have led to ~amage to the mucous memb-ranes of the nose and of the pharynx. This also applies to the known tests in earlier days using essential oils,such as for example menthol, camomile, eucalyptus oil, etc.
~` ~Z1623Z
It is the object of the present invention to make available a method and acomposition to overcome snoring, by the use of which even ser~ous cases of snoring can be prevented, with-out any harmful side-effects caused by adverse effects on the mucous membranes of the nose and pharynx. Namely the so-called common-snoring which is present with completely healthy people (in nose and mouth area) and therefore is essent-ially a sound phenomenon shall be overcome.
This object is attained by the invention in that a composition is made available which comprises the following su~stances:
..........
A surface active substance, a preserving agent and/or a substance acting upon the mu~us membranes bactericidally or fungicidally, and preferably a substance which makes the mucous membranes supple or soft, in physiological common salt solution, as well as optionally other additives which -are compatible with the mucous membranes.
By the method of use of the ccmposition accor~ng to the invention surprisingly snoring and namely common-snoring can be prevented or reduced when it is applied to the mucous mem-branes of the nose and pharynx of the persons concerned, whereby it keeps the mucous membranes of the nose and - 2S pharynx moist and where possible it cleanses them of dry mucous.
The composition according to the invention also ensures in several ways the smoothing of the surfaces which de-limit the flow channels. The mucous membranes which areexposed to daily strain from noxious agents can recover, tough mucus liquifies and again expands in the physiol-ogically necessary manner. Connected therewith is an increase of the normal functions to the point of optimal normal funktioning.
Z3~
Thus the effects of the agent according to the invention are based on the fact that snoring, which is caused inter alia by the drying out of the mucous membranes of the nose and pharynx, is prevented by the moistening as well as the possible purification of the mucous membranes.
.
The moistening of the mucous membranes is attained in the case of the composition according to the invention by a physio-logical common salt solution in connection with at least 10 one surface active agent. It has been possible to show that the adjustment of the physiological common sal~
? solution in respect of its sodium chloride content is not so critical, i.e. that the,common salt solution can also contain sodium chloride in concentrations deviating 5 from the physiological conditions.
The surface' active substances play a substantial part in ~e composition of the invention, in order to maintain con-tact and to improve it between the physiological co~mon 20 salt solution and the mucous membranes of the nose and pharynx; ~ere it is primarily important that the surface active substances should be compatible with the mucous membranes. It is preferable for the surface active sub-stances to be in a position to remove dry mucus residues on the mucous membranes of the nose and pharynx.
According tc the invention, anionic, cationic, amphot-eric and non-ionic surface active compounds are in 30 question.The important prerequisite for the surface-active substances is their compatibility with mucous membranes. In addition, they should have a pleasant smell and taste.
The non-ionic surface active substances have been shown 35 to be especially preferred. Since they do not have any - lZ1~23~
salt-forming groups, they are not reduced by bivalent or multivalent cations, so that they can be used prefer-ably in combination with other substances.
According to the invention, the preferable surface act-ive substances have been shown to be polyoxyalkylene derivatives of the sorbitanesters, i.e. sorbitanesters in which the free hydroxyl groups are etherified with a c~rtain numb r of ethyleneoxide molecules. The most use-ful of these ethers are those ~ which about 20 moles -:~ ethyleneoxide and more are condensed.
Polysorbate BO(Tween 80), a' non-ionic substance is an especially suitable product, which consists essentially of a monooleate ester of sorbitan which is etherified with about 90 moles ethyleneoxide.
Tween 20 is also suitable;it comprises a polyoxyethylene - derivative from sorbitanhydride, contains a lauryl radi-cal and is etherifed with about 20 oxyethylene groups.
Also sui.able are polyoxyethylenesorbitan monopalmit-ate ~Tween 40) and polyoxyethylenesorbitan monostearate _ (Tween 60).
Snoring is a phenomenon which is based on rhoncus S breathing, which may occur among hum~n beings during sleep. Du~ ';o the strain which snoring may place upon other human beings, many attempts have been made to provide a remedy for this phenomenon.
.,~
The cause of snoring are obstructions (unevenness) in the area of the upper respi~atory tracts. During in-halation and exhalation, the air is led via complex flow channels. Unevennesses in these areas lead neces-sarily to turbulences in the air flow. These cause ~5 impediments ~o breathing, which are below the conscious-nçss threshold. The impediments in the flow channels and the turbulences caused thereby have the consequence that locally a low pressure area(suction) is formed.
This leads to fluttering motions of soft,relaxed struct-ures in the area of the air flow channels. In particul--. ar the soft gums are moved backward and forward by tlle above-mentioned turbulences. Although numerous investig-ations have been carried out to preven' snoring, as yet - they have not led to the desired success. These efforts have been based on compositionswhich were built u~ on chel~lo-therapeutics or antibiotics, vasoactive substances, cor-ticoids or on antihistaminics. ~hese ccmpositions, ~.owever, have either proved to be not effective enough to pre-vent snoring over long periods, or when taken over leng-thy periods they have led to ~amage to the mucous memb-ranes of the nose and of the pharynx. This also applies to the known tests in earlier days using essential oils,such as for example menthol, camomile, eucalyptus oil, etc.
~` ~Z1623Z
It is the object of the present invention to make available a method and acomposition to overcome snoring, by the use of which even ser~ous cases of snoring can be prevented, with-out any harmful side-effects caused by adverse effects on the mucous membranes of the nose and pharynx. Namely the so-called common-snoring which is present with completely healthy people (in nose and mouth area) and therefore is essent-ially a sound phenomenon shall be overcome.
This object is attained by the invention in that a composition is made available which comprises the following su~stances:
..........
A surface active substance, a preserving agent and/or a substance acting upon the mu~us membranes bactericidally or fungicidally, and preferably a substance which makes the mucous membranes supple or soft, in physiological common salt solution, as well as optionally other additives which -are compatible with the mucous membranes.
By the method of use of the ccmposition accor~ng to the invention surprisingly snoring and namely common-snoring can be prevented or reduced when it is applied to the mucous mem-branes of the nose and pharynx of the persons concerned, whereby it keeps the mucous membranes of the nose and - 2S pharynx moist and where possible it cleanses them of dry mucous.
The composition according to the invention also ensures in several ways the smoothing of the surfaces which de-limit the flow channels. The mucous membranes which areexposed to daily strain from noxious agents can recover, tough mucus liquifies and again expands in the physiol-ogically necessary manner. Connected therewith is an increase of the normal functions to the point of optimal normal funktioning.
Z3~
Thus the effects of the agent according to the invention are based on the fact that snoring, which is caused inter alia by the drying out of the mucous membranes of the nose and pharynx, is prevented by the moistening as well as the possible purification of the mucous membranes.
.
The moistening of the mucous membranes is attained in the case of the composition according to the invention by a physio-logical common salt solution in connection with at least 10 one surface active agent. It has been possible to show that the adjustment of the physiological common sal~
? solution in respect of its sodium chloride content is not so critical, i.e. that the,common salt solution can also contain sodium chloride in concentrations deviating 5 from the physiological conditions.
The surface' active substances play a substantial part in ~e composition of the invention, in order to maintain con-tact and to improve it between the physiological co~mon 20 salt solution and the mucous membranes of the nose and pharynx; ~ere it is primarily important that the surface active substances should be compatible with the mucous membranes. It is preferable for the surface active sub-stances to be in a position to remove dry mucus residues on the mucous membranes of the nose and pharynx.
According tc the invention, anionic, cationic, amphot-eric and non-ionic surface active compounds are in 30 question.The important prerequisite for the surface-active substances is their compatibility with mucous membranes. In addition, they should have a pleasant smell and taste.
The non-ionic surface active substances have been shown 35 to be especially preferred. Since they do not have any - lZ1~23~
salt-forming groups, they are not reduced by bivalent or multivalent cations, so that they can be used prefer-ably in combination with other substances.
According to the invention, the preferable surface act-ive substances have been shown to be polyoxyalkylene derivatives of the sorbitanesters, i.e. sorbitanesters in which the free hydroxyl groups are etherified with a c~rtain numb r of ethyleneoxide molecules. The most use-ful of these ethers are those ~ which about 20 moles -:~ ethyleneoxide and more are condensed.
Polysorbate BO(Tween 80), a' non-ionic substance is an especially suitable product, which consists essentially of a monooleate ester of sorbitan which is etherified with about 90 moles ethyleneoxide.
Tween 20 is also suitable;it comprises a polyoxyethylene - derivative from sorbitanhydride, contains a lauryl radi-cal and is etherifed with about 20 oxyethylene groups.
Also sui.able are polyoxyethylenesorbitan monopalmit-ate ~Tween 40) and polyoxyethylenesorbitan monostearate _ (Tween 60).
2~ Further surface active substances such as Triton~ e.g.
from th~ firm Rohm & Haas, Philadelphia USA, are suitab-le as the surface active substances. Particularly suit-able is Triton ~R 1339.
Also suitable is Lecithine, as in the group of such type of compounds normally a hydrophilic glycerino phosphoric acid choline moiety and hydrophobic alkyl groups of fatty acids exist. Other examples of such type are tenside fatty alcohols and their derivatives.
~enDtes ~aJc ~a~l~
- ~21~2~2 According to the invention the surface-active substances a~ largely free of ~sirable smell or taste. It is especially advantageous when the surface active substance used also exercises a stimulating effect on the cilia.
s The surface active substance is added to the agent ac-cording to the invention in a oonoentration o~ preferably from o.05 to 2% by weight, based on the total weight of the com~o-sition.In most cases it it of adva~tage to work with lower concentrations of the surface active agent. For this purpose ~he surface a~tive ~ge~t is preferably added in a concentration of from 0.1 to O.S % by weight,while from 0.15 to 0.30% by weight are particularly preferred.
Further it may be of advantage that a preservinq agent is add-ed to the composition according to the inventionO This -~ is especially necessary in order to prevent a microbial growth in the composition itself, especially after it has been o~ened.
It is especially preferable if the added preserving agent can additionally ac~ upon the mucous membranes of the nose and pharynx cavities bactericidally and/or fungic-idally. ~o the extent that the preserving agent does not exert this effect or does not do so ade~uately, a suitable substance which acts upon the mucous membranes of the nose and pharynx bactericidally and/or fungicid-ally may be added to the composition according the the in-vention as a mucous membrane disinfectant.
As the preserving agent, those which are in general use in pharmaceutical preparations can be added, when they pxevent microbial growth and are not harmful in the use according to the invention. For example, ethanol, esters of the p-hydroxybenzoic acid, 2-phenoxy-~, ethanol, benzoic acid and its salts, sorbic acid and its esters etc. , Suitable mucous membrane disinfectants, which can take 5 effect both as disinfectant agents as well as'antisept-ics, are acridine and quinoline deriYatives, quaternary ammonium compounds as well as compounds with amidine structures.
.._ ~- 10 According to the invention particularly good results are obtained using benzalkonium chloride, which is a mild disinfectant compatible with the mucous membranes. It prevents any possible rapid new mucous obstruction,in that it wards off irritation due to impurities in the mucous membranes of the nose, and thereby reduces the irritation. Excessive mucus formation rapidly occurring would again trigger off the sn,oring, especially in connect~ -ion with the drying possibilities of the mucus.
Apart from the above-mentioned benzaIkonium chloride, other quaternary amines, to the extent that they are not ~- incompatible with the mucous membranes, are suitable ' as disinfectants in the composition according to the invention.
The use of benzododecinium has also shown itself to be suitable as a further mucus membrane disinfectant.
As the fungostatically effective agent, it has been found that the addition of chlorobutanol, a compound which has both bactericidal as well as fungostatic effects, is suitable.
The preservin(3 agents are added optionally to the compositions lZl~Z3Z
of the invention together with bactericidally or fungi-cidally effective substances in a concenlration of from 0,01 to 4% of theweigh~ based on the total weight of the compo-sition.Preferably the concentration of the bactericidal and fungostatic compounds amounts to O.O1 to O.O5 g, based on 1COO ml of the composition according to the invention.
Moreover the composition of the invention may contain pre-ferably substances which exercise a flexing or softenina influence on the mucous membranes of the nose and pharynx.
' The object of this softening agents for the mucous me~branes is to prevent the formation of microfissures in them o~ to cause their decline.
For this purpose the ~olyalcohols are suitable, which prevent the surface drying of the mucous membranes and in addition also reduce the surface tension of the water phase. The suitable polyalcohols include ethy-~ lene glycol, diethylene glycol, propylene glycol, di-propylene glycol, glycerol, diglycerol, butyl glycol-1,3 and sorbite. ~o the extent that the surface active sub-stance is a polyalcohol itself exhibiting the above proper-ties an additional softening agent is not required. If suchagent is used, however, glycerol and sorbite are especially suitable.
In addition the use of panthenol as a means for flexing the muoous membranes has been shown to be advantageous.
Panthenol is compatible with the mucous membranes and has an effect similar to that of pantothenicacid. Sim-ultaneously panthenol has a regenerating surface effect on the mucous membranes.
The substances for softening or flexing the mucous mem---` lZl~Z32 branes may be ~nt~d in the composition of the invention in a concentration of preferably from 0.1 t~ 1~ by weig~t based on the total weight of the composition, The preferred concent-ration range i5 from 0.2 to 0.4% by weight.
In addition substances which are compatible with the mucous membranes , which prevent the formation of micro-fissures or favor the removal of disturbing substances, can be added to the composition of the invention.
--..= 10 These additives should primarily contribute to the removal of deposits or the formation of tough mucus on the mucous membranes, or to the prevention thereof.
Therefore it may be ~t ~ s a~vantageo~C to add an en~m~
preparation which is compatible with mucous membranes and which promotes the dissolution of disturbing sub-stances to the composition of the invention. ~he suitable enzyme preparations are especially the hydrolases, l~pases and proteases. Here it is preferable to add enzyme products which,in the pH range to be found on the mucous membranes of the nose and pharynx,have at -= least approximately their pH optimum and are as far as ..... ~.
possible stable under the prevailing conditions.
Also vitamins such as vitamin A in an amount of about 15,000 IE/ml, and vitamin E, e.g. as acetate in an amount of about 20 mg/l, are suitable as additives compatible with the mucous membranes.
In addition it is advantageous to add to the comFosition of the invention substances compatible with mucous mem-branes such as the serolytics, e.g. acetyl cystein as well as compounds from the range of sympathomitetics, e.g. 2-amino-heptane, forthane,:2-amino-`` ii~l~`232 6-methyl heptane. Also substances like menthols, camomille, eucalyptus oils etc., can be usefulO
The formulations below are intended to define the agent of the invention more precisely, but without limiting it to the examples listed here. From the foregoing and the below examples it becomes clear that the compositions according to this invention preferably do not contain vaso-constrictive agents, hormones and antibiotics.
-,, 10 :.. _. .
Prescription 1 Sodium chloride 8.5 to 9.5 g Surface active agent (polysorbate 80~ 1~3 to 3.5 g Glycerol 2.0 to 4.0 g ethyl alcohol 90(vol/vol~ 3.0 to 8.0 g panthenol 1.5 to 4.0 g benzalkonium chloride 0.01 to 0.15 g demineralized water up to 1000 ml.
........ .
- Prescription 2 Polysorbate 80 2 g glycerol 3 g ethyl alcohol 90(vol/vol) 6 g benzalkonium chloride 0.02 g filled up with physiological common salt solution to 1000 ml.
Z~3~
Prescription 3 Lecithine 2.5-4 g dodecinium chloride 0.3 g 5 eucalyptus oil 1 g fatty alcohol emulsifier (trace) filled up with physiological common salt solution to 1000 ml ''' 1 0 The invention also comprises a process for the use of the inventive composition for overcoming snoring, which con-sists of applying the composition to the mucous membranes of the nose and pharynx of the person concerned with the aid of a suitable device and in adequate quantities.
To achieve the effect desired, relatively small amounts of the composition of the invention are sufficient, e.g. about O.S to 10 ml, preferably 1.0 to 2.0 ml. The co~sition of the invention is introduced or dripped into each nostril ~sing a suitable instrument or device, so that the liq-uid is applied to the mucous membranes of the nose and pharynx. Suitable devices to implement this procçss are known. For example the composition can be applied by an aero-sol device, by an atomizer, a rinsing pipette with individual ampules or individual dose ampules with pip-ette, or by pipette bottles which contain the composition.
The composition is taken in the evening before going to bed, either lying down or standing with head bent backward.
The application can be repeated during the night.
~Z~~2~3~
"
The tests carr~ed out on human beings have shown that the composition does not produce any incompatibilities, not even when used over long periods, because the components are not toxic in the concentrations stated above and the relevant components have already been used individualiy in rhinology.
In addi'ion the tests have shown that the co~positi~n ~ according to ~he invention is particularly effectiveand that ^- 10 the snoring is either wholly prevented or at least is greatly reduced.
, ...........
._ .
from th~ firm Rohm & Haas, Philadelphia USA, are suitab-le as the surface active substances. Particularly suit-able is Triton ~R 1339.
Also suitable is Lecithine, as in the group of such type of compounds normally a hydrophilic glycerino phosphoric acid choline moiety and hydrophobic alkyl groups of fatty acids exist. Other examples of such type are tenside fatty alcohols and their derivatives.
~enDtes ~aJc ~a~l~
- ~21~2~2 According to the invention the surface-active substances a~ largely free of ~sirable smell or taste. It is especially advantageous when the surface active substance used also exercises a stimulating effect on the cilia.
s The surface active substance is added to the agent ac-cording to the invention in a oonoentration o~ preferably from o.05 to 2% by weight, based on the total weight of the com~o-sition.In most cases it it of adva~tage to work with lower concentrations of the surface active agent. For this purpose ~he surface a~tive ~ge~t is preferably added in a concentration of from 0.1 to O.S % by weight,while from 0.15 to 0.30% by weight are particularly preferred.
Further it may be of advantage that a preservinq agent is add-ed to the composition according to the inventionO This -~ is especially necessary in order to prevent a microbial growth in the composition itself, especially after it has been o~ened.
It is especially preferable if the added preserving agent can additionally ac~ upon the mucous membranes of the nose and pharynx cavities bactericidally and/or fungic-idally. ~o the extent that the preserving agent does not exert this effect or does not do so ade~uately, a suitable substance which acts upon the mucous membranes of the nose and pharynx bactericidally and/or fungicid-ally may be added to the composition according the the in-vention as a mucous membrane disinfectant.
As the preserving agent, those which are in general use in pharmaceutical preparations can be added, when they pxevent microbial growth and are not harmful in the use according to the invention. For example, ethanol, esters of the p-hydroxybenzoic acid, 2-phenoxy-~, ethanol, benzoic acid and its salts, sorbic acid and its esters etc. , Suitable mucous membrane disinfectants, which can take 5 effect both as disinfectant agents as well as'antisept-ics, are acridine and quinoline deriYatives, quaternary ammonium compounds as well as compounds with amidine structures.
.._ ~- 10 According to the invention particularly good results are obtained using benzalkonium chloride, which is a mild disinfectant compatible with the mucous membranes. It prevents any possible rapid new mucous obstruction,in that it wards off irritation due to impurities in the mucous membranes of the nose, and thereby reduces the irritation. Excessive mucus formation rapidly occurring would again trigger off the sn,oring, especially in connect~ -ion with the drying possibilities of the mucus.
Apart from the above-mentioned benzaIkonium chloride, other quaternary amines, to the extent that they are not ~- incompatible with the mucous membranes, are suitable ' as disinfectants in the composition according to the invention.
The use of benzododecinium has also shown itself to be suitable as a further mucus membrane disinfectant.
As the fungostatically effective agent, it has been found that the addition of chlorobutanol, a compound which has both bactericidal as well as fungostatic effects, is suitable.
The preservin(3 agents are added optionally to the compositions lZl~Z3Z
of the invention together with bactericidally or fungi-cidally effective substances in a concenlration of from 0,01 to 4% of theweigh~ based on the total weight of the compo-sition.Preferably the concentration of the bactericidal and fungostatic compounds amounts to O.O1 to O.O5 g, based on 1COO ml of the composition according to the invention.
Moreover the composition of the invention may contain pre-ferably substances which exercise a flexing or softenina influence on the mucous membranes of the nose and pharynx.
' The object of this softening agents for the mucous me~branes is to prevent the formation of microfissures in them o~ to cause their decline.
For this purpose the ~olyalcohols are suitable, which prevent the surface drying of the mucous membranes and in addition also reduce the surface tension of the water phase. The suitable polyalcohols include ethy-~ lene glycol, diethylene glycol, propylene glycol, di-propylene glycol, glycerol, diglycerol, butyl glycol-1,3 and sorbite. ~o the extent that the surface active sub-stance is a polyalcohol itself exhibiting the above proper-ties an additional softening agent is not required. If suchagent is used, however, glycerol and sorbite are especially suitable.
In addition the use of panthenol as a means for flexing the muoous membranes has been shown to be advantageous.
Panthenol is compatible with the mucous membranes and has an effect similar to that of pantothenicacid. Sim-ultaneously panthenol has a regenerating surface effect on the mucous membranes.
The substances for softening or flexing the mucous mem---` lZl~Z32 branes may be ~nt~d in the composition of the invention in a concentration of preferably from 0.1 t~ 1~ by weig~t based on the total weight of the composition, The preferred concent-ration range i5 from 0.2 to 0.4% by weight.
In addition substances which are compatible with the mucous membranes , which prevent the formation of micro-fissures or favor the removal of disturbing substances, can be added to the composition of the invention.
--..= 10 These additives should primarily contribute to the removal of deposits or the formation of tough mucus on the mucous membranes, or to the prevention thereof.
Therefore it may be ~t ~ s a~vantageo~C to add an en~m~
preparation which is compatible with mucous membranes and which promotes the dissolution of disturbing sub-stances to the composition of the invention. ~he suitable enzyme preparations are especially the hydrolases, l~pases and proteases. Here it is preferable to add enzyme products which,in the pH range to be found on the mucous membranes of the nose and pharynx,have at -= least approximately their pH optimum and are as far as ..... ~.
possible stable under the prevailing conditions.
Also vitamins such as vitamin A in an amount of about 15,000 IE/ml, and vitamin E, e.g. as acetate in an amount of about 20 mg/l, are suitable as additives compatible with the mucous membranes.
In addition it is advantageous to add to the comFosition of the invention substances compatible with mucous mem-branes such as the serolytics, e.g. acetyl cystein as well as compounds from the range of sympathomitetics, e.g. 2-amino-heptane, forthane,:2-amino-`` ii~l~`232 6-methyl heptane. Also substances like menthols, camomille, eucalyptus oils etc., can be usefulO
The formulations below are intended to define the agent of the invention more precisely, but without limiting it to the examples listed here. From the foregoing and the below examples it becomes clear that the compositions according to this invention preferably do not contain vaso-constrictive agents, hormones and antibiotics.
-,, 10 :.. _. .
Prescription 1 Sodium chloride 8.5 to 9.5 g Surface active agent (polysorbate 80~ 1~3 to 3.5 g Glycerol 2.0 to 4.0 g ethyl alcohol 90(vol/vol~ 3.0 to 8.0 g panthenol 1.5 to 4.0 g benzalkonium chloride 0.01 to 0.15 g demineralized water up to 1000 ml.
........ .
- Prescription 2 Polysorbate 80 2 g glycerol 3 g ethyl alcohol 90(vol/vol) 6 g benzalkonium chloride 0.02 g filled up with physiological common salt solution to 1000 ml.
Z~3~
Prescription 3 Lecithine 2.5-4 g dodecinium chloride 0.3 g 5 eucalyptus oil 1 g fatty alcohol emulsifier (trace) filled up with physiological common salt solution to 1000 ml ''' 1 0 The invention also comprises a process for the use of the inventive composition for overcoming snoring, which con-sists of applying the composition to the mucous membranes of the nose and pharynx of the person concerned with the aid of a suitable device and in adequate quantities.
To achieve the effect desired, relatively small amounts of the composition of the invention are sufficient, e.g. about O.S to 10 ml, preferably 1.0 to 2.0 ml. The co~sition of the invention is introduced or dripped into each nostril ~sing a suitable instrument or device, so that the liq-uid is applied to the mucous membranes of the nose and pharynx. Suitable devices to implement this procçss are known. For example the composition can be applied by an aero-sol device, by an atomizer, a rinsing pipette with individual ampules or individual dose ampules with pip-ette, or by pipette bottles which contain the composition.
The composition is taken in the evening before going to bed, either lying down or standing with head bent backward.
The application can be repeated during the night.
~Z~~2~3~
"
The tests carr~ed out on human beings have shown that the composition does not produce any incompatibilities, not even when used over long periods, because the components are not toxic in the concentrations stated above and the relevant components have already been used individualiy in rhinology.
In addi'ion the tests have shown that the co~positi~n ~ according to ~he invention is particularly effectiveand that ^- 10 the snoring is either wholly prevented or at least is greatly reduced.
, ...........
._ .
Claims (40)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A composition for overcoming snoring, comprising a surface active substance in a concentration of from 0.05%
to 2% by weight, based on the total weight of the composition, and one or more agents selected from the group consisting of a preserving agent and a substance acting bactericidally or fungicidally on the mucous membrane, in physiologically common salt solution.
to 2% by weight, based on the total weight of the composition, and one or more agents selected from the group consisting of a preserving agent and a substance acting bactericidally or fungicidally on the mucous membrane, in physiologically common salt solution.
2. The composition according to claim 1, which further comprises a substance for softening the mucous membrane.
3. The composition according to claim 1, which further comprises additives which are compatible with the mucous membrane.
4. The composition according to claim 1, wherein it contains a polyoxyalkylene ester of sorbitan as the surface-active substance.
5. The composition according to claim 1, wherein it contains as the surface active substance polyoxyethylene sorbitan monocarboxylate.
6. The composition according to claim 1, wherein it contains as the surface active substance polyoxyethylene sorbitan monooleate.
7. The composition according to claim 1, 4 or 5, wherein it contains the surface active substance in a concentration of from 0.1% to 0.5% by weight, based on the total weight of the composition.
8. The composition according to claim 6, wherein it contains the surface active substance in a concentration of from 0.1%
to 0.5% by weight, based on the total weight of the composition.
to 0.5% by weight, based on the total weight of the composition.
9. The composition according to claim 1, wherein it contains a preserving agent selected from the group ethanol, esters of p-hydroxybenzoic acid, 2-phenoxyethanol, benzoic acid and its salts, sorbic acid and its esters.
10. The composition according to claim 1, wherein it contains as the mucous membrane disinfectant benzalkonium chloride.
11. The composition according to claim 1, wherein it contains the mucous membrane disinfectant chlorobutanol.
12. The composition according to claim 2, wherein it contains as the softening substance for the mucous membranes of the nose and pharynx one or both of glycerol and panthenol.
13. The composition according to claim 1, wherein it contains additionally one or more of the substances from the group vitamin A, vitamin E, hydrolases, lipases, proteases.
14. The composition according to claim 1, wherein the surface active substance is selected from the group consisting of fatty acid esters of oxyethylated sorbitol, sorbitane and pentaerythritol, and lecithines.
15. The composition according to claim 1, wherein the surface active substance is polyoxyethylene sorbitan monooleate.
16. The composition according to claim 1, wherein the surface active substance is lecithine.
17. The composition according to claim 14, wherein the surface active substance is included in a concentration of from 0.1% to 0.5% by weight, based on the total weight of the composition.
18. The composition according to claim 15, wherein the surface active substance is included in a concentration of from 0.1%
to 0.5% by weight, based on the total weight of the composition.
to 0.5% by weight, based on the total weight of the composition.
19. The composition according to claim 16, wherein the surface active substance is included in a concentration of from 0.1% to 0.5% by weight, based on the total weight of the composition.
20. The composition according to claim 17, wherein it contains a preserving agent selected from the group ethanol, esters of p-hydroxybenzoic acid, 2-phenoxyethanol, benzoic acid and its salts, sorbic acid and its esters.
21. The composition according to claim 18, wherein it contains a preserving agent selected from the group ethanol, esters of p-hydroxybenzoic acid, 2-phenoxyethanol, benzoic acid and its salts, sorbic acid and its esters.
22. The composition according to claim 19, wherein it contains a preserving agent selected from the group ethanol, esters of p-hydroxybenzoic acid, 2-phenoxyethanol, benzoic acid and its salts, sorbic acid and its esters.
23. The composition according to claim 20, wherein it contains the mucous membrane disinfectant selected from the group consisting of benzalkonium chloride and chlorobutanol.
24. The composition according to claim 21, wherein it contains the mucous membrane disinfectant selected from the group consisting of benzalkonium chloride and chlorobutanol.
25. The composition according to claim 22, wherein it contains the mucous membrane disinfectant selected from the group consisting of benzalkonium chloride and chlorobutanol.
26. The composition according to claim 23, wherein it contains a softening substance for the mucous membrane of the nose and pharynx selected from glycerol and panthenol.
27 The composition according to claim 24, wherein it contains a softening substance for the mucous membrane of the nose and pharynx selected from glycerol and panthenol.
28. The composition according to claim 25, wherein it contains a softening substance for the mucous membrane of the nose and pharynx selected from glycerol and panthenol.
29. The composition according to claim 26, wherein it contains additionally one or more of the substances from the group vitamin A, vitamin E, hydrolases, lipases, proteases.
30. The composition according to claim 27, wherein it contains additionally one or more of the substances from the group vitamin A, vitamin E, hydrolases, lipases, proteases.
31. The composition according to claim 28, wherein it contains additionally one or more of the substances from the group vitamin A, vitamin E, hydrolases, lipases, proteases.
32. A composition for overcoming snoring, comprising 0.05 to 2% by weight, based on the total weight of the composition, of polyoxyethylene sorbitan monooleate, benzalkonium choloride, and an alcohol selected from the group consisting of ethylalcohol, glycerine and sorbitol in a physiological sodium chloride solution.
33. A composition and applicator for overcoming snoring, which comprises the composition of (a) a surface active substance and (b) an agent selected from the group consisting of a preserving agent and a substance acting bactericidally or fungicidally on the mucous membrane, in a physiologically common salt solution; and applicator means for administering into each nostril of a victim of snoring, an amount from about 1 ml to about 2 ml of the composition.
34. The composition and applicator according to claim 33, wherein the surface active substance is included in a concentration of from 0.05 to 2% by weight, based on the total weight of the composition, and wherein the surface active substance is selected from the group consisting of fatty acid esters of oxyethylated sorbitol, sorbitane and pentaerythritol, and lecithines.
35. The composition and applicator according to claim 34, wherein the surface active agent is selected from polyoxyethylene sorbitan monoleate and lecithine and is included in a concentration of from 0.1% to 0.5% by weight, based on the total weight of the composition.
36. The composition and applicator according to claim 35, wherein it contains a preserving agent selected from the group ethanol, esters of p-hydroxybenzoic acid, 2-phenoxyethanol, benzoic acid and its salts, sorbic acid and its esters.
37. The composition and applicator according to claim 36, wherein it contains the mucous membrane disinfectant selected from the group consisting of benzalkonium chloride, chlorobutanol and benzododecinium.
38. The composition and applicator according to claim 23, wherein it contains a softening substance for the mucous membrane of the nose and pharynx selected from glycerol and panthenol.
39. The composition according to claim 38, wherein it contains additionally one or more of the substances from the group vitamin A, vitamin E, hydrolases, lipases, proteases.
40. The composition and applicator according to claim 33, wherein the composition comprises 0.05 to 2% by weight, based on the total weight of the composition, of polyoxyethylene sorbitan monooleate, benzalkonium chloride, and an alcohol selected from the group consisting of ethylalcohol, glycerine and sorbitol in a physiological sodium chloride solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000429349A CA1216232A (en) | 1983-05-31 | 1983-05-31 | Composition and process for overcoming snoring |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000429349A CA1216232A (en) | 1983-05-31 | 1983-05-31 | Composition and process for overcoming snoring |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1216232A true CA1216232A (en) | 1987-01-06 |
Family
ID=4125370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000429349A Expired CA1216232A (en) | 1983-05-31 | 1983-05-31 | Composition and process for overcoming snoring |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1216232A (en) |
-
1983
- 1983-05-31 CA CA000429349A patent/CA1216232A/en not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4556557A (en) | Method and composition for combating snoring, and the use of surface active substances for the preparation of said composition | |
| US6316483B1 (en) | Oxymetazoline HCI and/or chlorpheniramine maleate nasal spray compositions | |
| US6673835B1 (en) | Method and composition for delivering zinc to the nasal membrane | |
| US5801161A (en) | Pharmaceutical composition for the intranasal administration of hydroxocobalamin | |
| CA2842454C (en) | Nasal spray | |
| US4876283A (en) | Antisnoring agent | |
| MX169948B (en) | ANESTHETIC COMPOSITION FOR WET SKIN AND METHOD FOR PREPARING IT | |
| CA2039055A1 (en) | Treatment of sinus headache | |
| ATE213626T1 (en) | SOLID THERAPEUTIC OR HYGIENIC MUCOADHESIVE COMPOSITION FOR ADMINISTRATION BY APPLICATION TO THE ORAL MUCOSA OR NASAL MUCOSA | |
| CA1223210A (en) | Antisnoring agent | |
| WO2004024122A1 (en) | Composition and method for moisturizing nasal tissue | |
| US4892877A (en) | Antitussive liquid compositions containing phenol | |
| DE3601923A1 (en) | NASAL APPLICABLE MEDICINE, METHOD FOR THE PRODUCTION AND USE THEREOF | |
| CA1216232A (en) | Composition and process for overcoming snoring | |
| DE3610997A1 (en) | AMBROXOL NOSE SPRAY | |
| KR900701278A (en) | Bile acids for the treatment of viral infections | |
| JPH0253728A (en) | Medicine for prevention of snore | |
| JPH10130148A (en) | Composition for nebulizer | |
| JP2004075571A (en) | Nasal drop and method for producing the same | |
| EP0666078A2 (en) | Nasal spray compositions | |
| JPH0662442B2 (en) | Nasal drops | |
| DE4226217A1 (en) | Treatment of "dry nose" using a surfactant - opt. combined with preservatives and/or bactericides and fungicides in physiological saline, to regulate the moisture content of nose and throat | |
| DE3917109A1 (en) | Compsns. for controlling snoring - contg. surfactant and preservative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |